Related Experiment Video
Updated: Apr 21, 2026
Long-term Live-cell Imaging to Assess Cell Fate in Response to Paclitaxel
Published on: May 14, 2018
Sensitization of cervical carcinoma cells to paclitaxel by an IPP5 active mutant
Qi-Yan Zeng1, Yu Huang, Lin-Jie Zeng
1Department of Biochemistry and Molecular Biology, Guangxi Medical University, Nanning, Guangxi, China
Abstract:
Paclitaxel is one of the best anticancer agents that has been isolated from plants, but its major disadvantage is its dose-limiting toxicity. In this study, we obtained evidence that the active mutant IPP5 (8-60hIPP5m), the latest member of the inhibitory molecules for protein phosphatase 1, sensitizes human cervix carcinoma cells HeLa more efficiently to the therapeutic effects of paclitaxel. The combination of 8-60hIPP5m with paclitaxel augmented anticancer effects as compared to paclitaxel alone as evidenced by reduced DNA synthesis and increased cytotoxicity in HeLa cells. Furthermore, our results revealed that 8-60hIPP5m enhances paclitaxel- induced G2/M arrest and apoptosis, and augments paclitaxel-induced activation of caspases and release of cytochrome C. Evaluation of signaling pathways indicated that this synergism was in part related to down- regulation of NF-?B activation and serine/threonine kinase Akt pathways. We noted that 8-60hIPP5m down- regulated the paclitaxel-induced NF-?B activation, I?Bα degradation, PI3-K activity and phosphorylation of the serine/threonine kinase Akt, a survival signal which in many instances is regulated by NF-?B. Together, our observations indicate that paclitaxel in combination with 8-60hIPP5m may provide a therapeutic advantage for the treatment of human cervical carcinoma.
Insights
Adding 8-60hIPP5m to paclitaxel enhances its anticancer effects in cervical cancer cells. This combination therapy reduces DNA synthesis and increases cell death, offering a potential therapeutic advantage.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Paclitaxel is a potent anticancer drug derived from plants.
- Its clinical use is limited by dose-dependent toxicity.
- Novel strategies are needed to enhance paclitaxel efficacy and reduce toxicity.
Purpose of the Study:
- To investigate the potential of 8-60hIPP5m, an inhibitor of protein phosphatase 1, to sensitize human cervical carcinoma cells (HeLa) to paclitaxel.
- To elucidate the molecular mechanisms underlying the combined effects of 8-60hIPP5m and paclitaxel.
Main Methods:
- Treatment of HeLa cells with paclitaxel alone and in combination with 8-60hIPP5m.
- Assessment of DNA synthesis, cytotoxicity, cell cycle progression (G2/M arrest), apoptosis, caspase activation, and cytochrome C release.
- Analysis of signaling pathways, including NF-κB and Akt.
Main Results:
- 8-60hIPP5m significantly enhanced the anticancer effects of paclitaxel in HeLa cells.
- The combination therapy led to reduced DNA synthesis and increased cytotoxicity.
- 8-60hIPP5m augmented paclitaxel-induced G2/M arrest, apoptosis, caspase activation, and cytochrome C release.
- Synergistic effects were associated with the downregulation of NF-κB and Akt signaling pathways.
Conclusions:
- The combination of 8-60hIPP5m with paclitaxel demonstrates enhanced anticancer activity against human cervical carcinoma cells.
- This combination therapy may offer a promising therapeutic strategy for cervical cancer treatment by overcoming paclitaxel resistance and toxicity.
More Related Videos
Related Concept Videos
01:15Drugs that Stabilize Microtubules
01:31The Intrinsic Apoptotic Pathway
02:23Abnormal Proliferation